AUTEK(SZ:300595) Xin Lang Zheng Quan·2025-09-15 13:30Core Insights - The company participated in an online investor meeting on September 15, 2025, discussing business adjustments and new product developments [1][2]. Group 1: Business Adjustments - The decline in revenue from nursing products was attributed to the restructuring of online business and the cessation of partnerships with certain clients, leading to decreased distribution income [3]. - The company is exploring entry into the CPO, smart glasses, and brain-machine interface sectors through equity participation, having already established a partnership with Raytheon and Huiding for smart glasses, with the joint venture registered [3]. Group 2: New Products - Inquiries regarding the launch timeline for new products such as AI glasses and atropine eye drops were addressed, indicating that AI glasses are in preliminary preparation while atropine is still in phase III clinical trials, with disclosures to follow regulatory requirements [3]. - The company has launched scleral lenses in the first half of the year, aiming to capture a portion of the high-end frame market, although specific pricing strategies were not disclosed [3]. Group 3: Stock Repurchase - The company stated that any matters related to stock repurchase and cancellation would be disclosed in accordance with regulations, emphasizing that the meeting did not involve any undisclosed significant information [3].